AQST
Price
$5.29
Change
-$0.28 (-5.02%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
646.01M
116 days until earnings call
Intraday BUY SELL Signals
MKGAF
Price
$141.75
Change
+$11.16 (+8.55%)
Updated
Nov 13 closing price
Capitalization
58.31B
Intraday BUY SELL Signals
Interact to see
Advertisement

AQST vs MKGAF

Header iconAQST vs MKGAF Comparison
Open Charts AQST vs MKGAFBanner chart's image
Aquestive Therapeutics
Price$5.29
Change-$0.28 (-5.02%)
Volume$86.64K
Capitalization646.01M
Merck KGaA
Price$141.75
Change+$11.16 (+8.55%)
Volume$206
Capitalization58.31B
AQST vs MKGAF Comparison Chart in %
View a ticker or compare two or three
VS
AQST vs. MKGAF commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a Hold and MKGAF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (AQST: $5.58 vs. MKGAF: $130.59)
Brand notoriety: AQST and MKGAF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AQST: 94% vs. MKGAF: 24%
Market capitalization -- AQST: $646.01M vs. MKGAF: $58.31B
AQST [@Pharmaceuticals: Generic] is valued at $646.01M. MKGAF’s [@Pharmaceuticals: Generic] market capitalization is $58.31B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AQST’s FA Score shows that 0 FA rating(s) are green whileMKGAF’s FA Score has 1 green FA rating(s).

  • AQST’s FA Score: 0 green, 5 red.
  • MKGAF’s FA Score: 1 green, 4 red.
According to our system of comparison, AQST is a better buy in the long-term than MKGAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AQST’s TA Score shows that 4 TA indicator(s) are bullish while MKGAF’s TA Score has 3 bullish TA indicator(s).

  • AQST’s TA Score: 4 bullish, 5 bearish.
  • MKGAF’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, AQST is a better buy in the short-term than MKGAF.

Price Growth

AQST (@Pharmaceuticals: Generic) experienced а -7.00% price change this week, while MKGAF (@Pharmaceuticals: Generic) price change was -0.89% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.08%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +32.16%.

Reported Earning Dates

AQST is expected to report earnings on Mar 10, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MKGAF($58.3B) has a higher market cap than AQST($646M). AQST YTD gains are higher at: 56.742 vs. MKGAF (-13.836). MKGAF has higher annual earnings (EBITDA): 5.87B vs. AQST (-47.5M). MKGAF has more cash in the bank: 1.57B vs. AQST (60.5M). AQST has less debt than MKGAF: AQST (40.3M) vs MKGAF (9.4B). MKGAF has higher revenues than AQST: MKGAF (21.2B) vs AQST (44.1M).
AQSTMKGAFAQST / MKGAF
Capitalization646M58.3B1%
EBITDA-47.5M5.87B-1%
Gain YTD56.742-13.836-410%
P/E RatioN/A18.56-
Revenue44.1M21.2B0%
Total Cash60.5M1.57B4%
Total Debt40.3M9.4B0%
FUNDAMENTALS RATINGS
AQST vs MKGAF: Fundamental Ratings
AQST
MKGAF
OUTLOOK RATING
1..100
6319
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
23
Undervalued
PROFIT vs RISK RATING
1..100
92100
SMR RATING
1..100
10069
PRICE GROWTH RATING
1..100
3973
P/E GROWTH RATING
1..100
10081
SEASONALITY SCORE
1..100
502

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MKGAF's Valuation (23) in the null industry is in the same range as AQST (37) in the Pharmaceuticals Major industry. This means that MKGAF’s stock grew similarly to AQST’s over the last 12 months.

AQST's Profit vs Risk Rating (92) in the Pharmaceuticals Major industry is in the same range as MKGAF (100) in the null industry. This means that AQST’s stock grew similarly to MKGAF’s over the last 12 months.

MKGAF's SMR Rating (69) in the null industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that MKGAF’s stock grew similarly to AQST’s over the last 12 months.

AQST's Price Growth Rating (39) in the Pharmaceuticals Major industry is somewhat better than the same rating for MKGAF (73) in the null industry. This means that AQST’s stock grew somewhat faster than MKGAF’s over the last 12 months.

MKGAF's P/E Growth Rating (81) in the null industry is in the same range as AQST (100) in the Pharmaceuticals Major industry. This means that MKGAF’s stock grew similarly to AQST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AQSTMKGAF
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
69%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
65%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 25 days ago
85%
Bullish Trend 2 days ago
57%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 10 days ago
64%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
AQST
Daily Signal:
Gain/Loss:
MKGAF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NOA14.440.27
+1.91%
North American Construction Group Ltd
CHPGU10.290.02
+0.19%
Championsgate Acquisition Corp
RVTY94.13-0.18
-0.19%
Revvity
ANIP87.27-1.27
-1.43%
ANI Pharmaceuticals
AMTD0.89-0.06
-6.30%
AMTD IDEA Group

AQST and

Correlation & Price change

A.I.dvisor tells us that AQST and NBIX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AQST and NBIX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
-1.93%
NBIX - AQST
30%
Poorly correlated
-0.30%
ESPR - AQST
28%
Poorly correlated
-2.26%
HROW - AQST
27%
Poorly correlated
-0.77%
ACET - AQST
26%
Poorly correlated
+6.24%
CPHI - AQST
26%
Poorly correlated
-0.58%
More

MKGAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MKGAF has been loosely correlated with MKKGY. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MKGAF jumps, then MKKGY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MKGAF
1D Price
Change %
MKGAF100%
+0.83%
MKKGY - MKGAF
49%
Loosely correlated
+2.75%
AQST - MKGAF
19%
Poorly correlated
-1.93%
INDV - MKGAF
17%
Poorly correlated
-3.12%
EVO - MKGAF
17%
Poorly correlated
+5.72%
EBS - MKGAF
16%
Poorly correlated
-0.64%
More